Polymyalgia Rheumatica Clinical Trials

83 clinical trials for Polymyalgia Rheumatica across international registries, including 17 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica — RECRUITING · PHASE4
• Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica — RECRUITING · PHASE3
• A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy — RECRUITING
• Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency — RECRUITING · PHASE4
• Rheumatology Patient Registry and Biorepository — RECRUITING
• Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment — RECRUITING · PHASE4
• Using Novel Imaging to Rethink Diagnostic and Treatment Strategies for Polymyalgia Rheumatica — RECRUITING
• Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ) — RECRUITING
• Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy — RECRUITING
• Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica — RECRUITING · PHASE3
• Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic — RECRUITING
• AYLo - AutoimmunitY and Loss of y — RECRUITING
• Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis — RECRUITING
• Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) — RECRUITING
• Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases — RECRUITING · PHASE4
• A MULTI-CENTER, OPEN-LABEL EXTENSION STUDY OF SUBCUTANEOUS SECUKINUMAB TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY IN POLYMYALGIA RHEUMATICA (PMR) — RECRUITING
• DANIsh VASculitis Database (DANIVAS) — RECRUITING
• A 2-week single-blind, randomized, 3-arm proof of concept study of the effects of AIN457 (anti-IL17 antibody), ACZ885 (canakinumab, anti-IL1b antibody), or corticosteroids in patients with polymyalgia rheumatica, followed by an open label phase to assess safety and long term efficacy — TERMINATED · PHASE2
• DNA Methylation in PMR — NOT_YET_RECRUITING
• Using Personalized Rehabilitation to Reduce Disease and Increase Activity of Patients With Polymyalgia Rheumatica — NOT_YET_RECRUITING · NA
• Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) — ACTIVE_NOT_RECRUITING · PHASE3
• Assessment of osteoporosis knowledge in patients with inflammatory rheumatic diseases using the German version of the OKAT – a non-interventional cross-sectional study — NOT_YET_RECRUITING
• Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE) — ACTIVE_NOT_RECRUITING · PHASE3
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) — COMPLETED · PHASE3
• Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study) — TERMINATED · PHASE3
• PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS — ACTIVE_NOT_RECRUITING
• Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS — COMPLETED · PHASE3
• Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalgia Rheumatica (JADORE) — NOT_YET_RECRUITING
• Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica. — COMPLETED
• Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR — COMPLETED · PHASE1
• A randomized, double blind, placebo-controlled, phase II, multicentre trial to explore the efficacy and safety of oral AP1189 tablets administered at the dose 100 mg/day for 12 weeks in patients diagnosed with polymyalgia rheumatica and in remission on glucocorticoid — NOT_YET_RECRUITING · PHASE2
• Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rheumatica — NOT_YET_RECRUITING
• Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse — ACTIVE_NOT_RECRUITING · PHASE3
• Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed — COMPLETED · PHASE3
• Treat-to-target Prednisolon Taper in Patients With Polymyalgia Rheumatica — ACTIVE_NOT_RECRUITING · NA
• A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheumatica (PMR) — TERMINATED · PHASE3
• Implementation of a Research Infrastructure Network to enable healthservice research in general practice in Baden-Wuerttemberg (FoPraNet-BW) - Observational study „Polymyalgia rheumatica“ — OTHER
• Improved Diagnostics and Monitoring of Polymyalgia Rheumatica — ACTIVE_NOT_RECRUITING
• Screen for Early Diagnosis II: upgrading university-level rheumatological early care with a focus on the delegability of tasks to clinical nurse specialists — OTHER
• A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR) — TERMINATED · PHASE1
• A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR) — COMPLETED · PHASE2
• Validation of the PMR Activity Score and Evolution of Patient-reported Outcomes in Patients With Polymyalgia Rheumatica — COMPLETED
• REDUCE PMR: Rituximab Effect on Decreasing glUcoCorticoid Exposition in relapsing PolyMyalgia Rheumatica — TERMINATED · PHASE4
• A trial of prednisolone in combination with SPI-62 or placebo in participants with polymyalgia rheumatica (PMR) — OTHER · PHASE2
• A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases. — NOT_YET_RECRUITING
• A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of Baricitinib as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects with New-Onset Polymyalgia Rheumatica (JAK-SPARE 1) — OTHER · PHASE3
• REDUCE PMR: Rituximab Effect on Decreasing glUcoCorticoid Exposition in newly diagnosed PolyMyalgia Rheumatica — OTHER · PHASE4
• A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 — TERMINATED · PHASE2
• Leflunomide in PMR; A multicenter randomized placebo controlled treatment study of Leflunomide in polymyalgia rheumatica — TERMINATED · PHASE3
• A trial of prednisolone in combination with SPI-62 in participants with polymyalgia rheumatica (PMR) — OTHER · PHASE1

Refine this search